Global Pharma Sales Growth Slows To Record Low Thanks To Recession - IMS
This article was originally published in The Pink Sheet Daily
Executive Summary
A revised forecast by IMS Health sees just 2.5 percent to 3.5 percent growth this year, with currency fluctuations getting much of the blame.
You may also be interested in...
Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.
Coupon Redemption On The Rise: A Recession-Proof Boost For Scripts?
Coupon redemptions for prescription drugs more than doubled in 2008 compared to 2007, according to a telephone and internet study of 8,700 consumers conducted by Manhattan Research, a research division of Decision Resources
The John Green Effect: Will Industry Be Influenced Again?
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.